My lab is interested in finding targets for T cell therapy of Multiple Myeloma and other Monoclonal Gammopathies, such as Waldenstrom’s Macroglobulinemia. The ultimate goal of this research is to translate findings from tissue culture and mouse studies into immunotherapies for Myeloma patients. Thus far we have identified 2 potentially relevant peptides from the candidate myeloma antigen MAGE-C1 (CT-7), a cancer testis antigen, and we are also looking for epitopes from other candidate antigens. We are using various methods including reverse immunology as well as vaccination of HLA-A2 transgenic mice with gene-modified cellular vaccines to elicit T-cell responses.
Another goal of the lab is to identify the targets recognized by T-cells in the setting of Graft versus Myeloma responses and Graft versus Waldenstrom’s following Allogeneic Stem Cell Transplantation.
RESEARCH INTERESTS
Multiple Myeloma
Cancer immunology
MAGE-C1 (CT-7)
Immunotherapy
Stem Cell Transplantation
RECENT PUBLICATIONS
Anderson LD Jr, Cook DR, Berger C, Maloney D, and Riddell SR, "Use of Gene-Modified T-cells as Antigen Presenting Cells (T-APC) for Vaccination against Myeloma Antigens." Blood, 110:Abstract #2758, November 2007
Anderson LD Jr, Sandmaier BM, Maris MB, et al, "Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstrom s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect." Blood, 108:Abstract #3034, November 2006
Anderson LD Jr, Maloney DG, and Riddell SR, "Generation of T-cells reactive against CT-7 and BCMA peptides: Potential targets for T-cell immunotherapy of multiple myeloma." Journal of Clinical Oncology, 24:Abstract #7615, June 2006
SIGNIFICANT PUBLICATIONS
Anderson LD Jr, Mori S, Mann S, Savary CA, and Mullen CA, "Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease." Cancer Research, 60:5797-5802, October 2000
Anderson LD Jr, Savary CA, and CA Mullen, "Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease" Blood, 95:2426-2433, April 2000
Anderson LD Jr, Petropoulos D, Everse LA, and Mullen CA, "Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine" Cancer Research, 59:1525-1530, October 1999
Anderson LD Jr, Hudson JM, Savary CA, Fisk B, Gershenson DM, and Ioannides CG, "HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells." Cancer Immunology Immunotherapy, 48:401-410, October 1999
Mullen CA, Anderson L, Woods K, Nishino M, and Petropoulos D, "Ganciclovir chemoablation of herpes simplex thymidine kinase suicide gene-modified tumors produces tumor necroses and induces systemic immune responses." Human Gene Therapy, 1998:2019-2030, September 1998
Everse LA, Anderson LD Jr, Rooijen N van, and Mullen CA, "Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate graft-versus-host disease and increases peri-BMT mortality." Transplantation, 71:611-618, March 2001
Point and right click (click and hold for Mac users) your mouse onand select "Save this link (or target) as..." option to save the file to your local computer.
and select "Save this link (or target) as..." option to save the file to your local computer.